Brodalumab: Extension study data

Amgen reported data from 156 patients with psoriatic arthritis in the open-label extension of a double-blind, placebo-controlled, U.S. and Canadian Phase II trial of subcutaneous brodalumab. At week 12 in the Phase II trial, all patients were offered open-label 280 mg brodalumab every 2 weeks for up to 5 years; patients received placebo or 140 or 280 mg brodalumab on day 1 and at weeks 1, 2, 4, 6, 8 and 10 in the Phase II trial.

In the extension, ACR20 response rates at week 24 were 51% for patients who initially received low-dose brodalumab and 64% for patients who initially received high-dose brodalumab vs. 44% of patients who initially received placebo and switched to high-dose brodalumab at week 12. ACR50 response rates at week 24 were 33% for both groups of patients who initially received brodalumab vs. 20% for patients who initially received placebo. ...